mRNA-based prophylactic vaccinesin collaboration with GSK
Addressing infectious diseases
Multivalent Constructs
Influenza vaccine candidates(Modified mRNA)
Partner
FLU SV mRNA
Influenza vaccine candidate(Modified mRNA)
Partner
CVSQIV
Influenza vaccine candidate(Unmodified mRNA)
Partner
Mono- and bivalent constructs
COVID-19 vaccine candidates(Modified mRNA)
Partner
CV0501
COVID-19 vaccine candidate(Modified mRNA)
Partner
CV2CoV
COVID-19 vaccine candidate(Unmodified mRNA)
Partner
Other infectious diseases
Partner
mRNA-based prophylactic vaccines
Addressing infectious diseases
CV7202
Rabies vaccine candidate
CV7202 – Phase 1
CV7202 is a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein, RABV-G, formulated with next generation lipid nanoparticle (LNP).
CV7202 is currently being studied in a phase 1, dose-escalation, open-label clinical trial.
Study objectives:
- Primary: Safety, reactogenicity
- Secondary: Potential protective immune response, immunogenicity via geometric mean virus neutralization tests (VNT)
Rabies, a viral disease that causes inflammation in the brain, still occurs in more than 150 countries around the globe, with the infection responsible for more than 60,000 deaths every year, primarily in China and India.
More information about the CV7202 study can be found at ClinicalTrials.gov (NCT03713086).
Lassa, yellow fever
Partner
Various projects
Rota, malaria, universal influenza
Partner
Ongoing Research – Malaria & Rota – Research
With support from the Bill & Melinda Gates Foundation, research is being conducted to leverage CureVac’s prophylactic vaccine technology to develop mRNA-based vaccines to prevent infectious diseases that disproportionately affect people in the world’s poorest countries.
RNA-based cancer immunotherapies
CVGBM
Multi-epitope mRNA cancer vaccine candidateSurgically resected glioblastoma
CV8102
Non-coding RNA oncology candidateSolid tumors
CV8102 (Study 1) – Phase 1
CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA, is designed to modulate the tumor microenvironment after intratumoral injection and to induce a systemic immune response to control injected as well as non-injected distant lesions.
CV8102 is currently being studied in a Phase 1, open-label, dose escalation and expansion study, which is enrolling patients with advanced melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma, and superficially injectable tumor lesions.
The trial is testing escalating doses of single agent CV8102 and CV8102 in combination with licensed anti-PD-1 antibodies.
Study objectives:
- Primary: Safety, tolerability
- Secondary: Clinical efficacy, changes in various immune parameters in blood and tumor tissue
More information about the CV8102 study can be found at ClinicalTrials.gov.
Tumor associated antigens (TAA)
Undisclosed
Shared neo-antigens
Undisclosed
Molecular therapies
Cas9 gene-editing
Partner
Gene-editing – Pre-clinical
CureVac is collaborating with CRISPR Therapeutics to develop novel Cas9 mRNA constructs, which have improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.
For more information about our partnership with CRISPR click here.
Liver Diseases
Ocular diseases
Partner
Therapeutic antibodies
Partner